Jasper Therapeutics, recently facing financial difficulties and pipeline development delays that threatened its listing, has acquired Kira Pharmaceuticals, a private, complement-focused biotech company, through a stock-for-stock exchange. This acquisition is part of a survival strategy aimed at overcoming its reliance on a single pipeline and rapidly expanding its complement-targeted portfolio to rebuild its corporate value. The merged entity will incorporate Jasper's existing KIT inhibitor antibody and a range of Kira's validated immune disease candidates, creating a new pipeline. The combination of the two companies' technologies represents more than just a merger; it is a platform for addressing the unmet needs in autoimmune diseases.

The key asset in this merger is the acquisition of full rights to KP104, Kira's Phase 2 C5/Factor D dual-targeting biologic, which is being developed as a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Lupus Nephritis (LN), and aims to provide more potent therapeutic efficacy than existing C5 single inhibitors. This is combined with Briquilimab, Jasper's Phase 1b/2 treatment for Chronic Spontaneous Urticaria (CSU), to maximize synergy. The combination and integration of the two candidates aim to enhance the immune regulation platform and strengthen its global market position.

In conjunction with the acquisition, Kira has out-licensed its early-stage complement target assets, KP-301 (long-acting anti-C5a monoclonal antibody) and KP-402 (C5a receptor antagonist small molecule compound), to Mirador Therapeutics. Mirador will pay an upfront payment of $12 million, along with additional milestone payments and royalties based on future clinical progress, contributing to initial cash flow. Simultaneously, Jasper successfully raised $132 million through a private placement, alleviating market concerns. This financial decision aims to prevent post-merger financial difficulties and create a stable environment for focusing on research and development.

The $132 million in private placement funding and the upfront payment from the license agreement are expected to extend the cash runway of the combined entity to the second half of 2028. This resolves the most critical financial liquidity risk in the long-term battle of drug development and provides time to independently accumulate late-stage clinical data. The industry is watching to see whether the merged entity will emerge as a real competitor to AstraZeneca and Novartis in the global PNH and CSU markets. The subsequent clinical data for KP104 and Briquilimab will be the key to driving further increases in corporate value.